Johnson & Johnson has reported Phase III data where CARVYKTI improved overall survival in patients with multiple myeloma.

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...

The trial enrolled chronic myeloid leukaemia patients irrespective of their T315I mutation status. Credit: Nemes Laszlo/Shutterstock. Enliven Therapeutics has reported the latest positive results from ...